Novel N-aryl(alkaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6- yl)thio]acetamides: Synthesis, cytotoxicity, anticancer activity, COMPARE analysis and docking

Medicinal Chemistry Research

Volumn 22, Issue 6, 2013, Pages 2610-2632

  Kovalenko, Sergey I ^a   Nosulenko, Inna S ^a   Voskoboynik, Alexey Yu ^a   Berest, Galina G ^a   Antipenko, Lyudmila N ^a   Antipenko, Alexey N ^a   Katsev, Andrey M ^b  

^a ZAPORIZHZHIA STATE MEDICAL UNIVERSITY   (Ukraine)

^b V I VERNADSKY CRIMEAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

Anticancer; Bioluminescence; Cytotoxicity; Docking; N Aryl(alkaryl) 2 (3 R 2 oxo 2H 1,2,4 triazino 2,3 c guinazoline 6 yl) thio acetamides

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; LAPATINIB; N (2 CHLOROPHENYL) 2 [(2 OXO 3 (4 METHOXYPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (2 FLUOROPHENYL) 2 [(2 OXO 3 (4 METHOXYPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (2 FLUOROPHENYL) 2 [(2 OXO 3 (4 METHYLPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (2 FLUOROPHENYL) 2 [(2 OXO 3 METHYL 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (2 METHOXYPHENYL) 2 [(2 OXO 3 PHENYL 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (2 METHYLPHENYL) 2 [(2 OXO 3 (4 METHOXYPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (2 METHYLPHENYL) 2 [(2- OXO 3 (4 METHYLPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (2 NITROPHENYL) 2 [(2 OXO 3 (4 METHYLPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (2 TRIFLUOROPHENYL) 2 [(2 OXO 3 (4 METHOXYPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (2 TRIFLUOROPHENYL) 2 [(2 OXO 3 METHYL 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (3 CHLOROPHENYL) 2 [(2 OXO 3 PHENYL 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (3 FLUOROPHENYL) 2 [(2 OXO 3 (4 METHYLPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (3 FLUOROPHENYL) 2 [(2 OXO 3 PHENYL 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (3 METHYLPHENYL) 2 [(2 OXO 3 METHYL 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (3 TRIFLUOROPHENYL) 2 [(2 OXO 3 (4 METHYLPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (3 TRIFLUOROPHENYL) 2 [(2 OXO 3 PHENYL 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (4 CHLOROPHENYL) 2 [(2 OXO 3 (4 METHYLPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (4 CHLOROPHENYL) 2 [(2 OXO 3 METHYL 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (4 CHLOROPHENYL) 2 [(2 OXO 3 PHENYL 2H [1,2,4]TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (4 FLUOROPHENYL) 2 [(2 OXO 3 (4 METHYLPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (4 METHOXYPHENYL) 2 [(2 OXO 3 (4 METHYLPHENYL) 2H [1,2,4] TRIAZINO [2,3 C] QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (4 METHYLPHENYL) 2 [(2 OXO 3 (4 METHOXYPHENYL) 2H [1,2,4] TRIAZINO [2,3 C] QUINAZOLIN 6 YL)THIO]ACETAMIDE; N (4 TRIFLUOROPHENYL) 2 [(2 OXO 3 (4 METHYLPHENYL) 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N PHENYL 2 [(2 OXO 3 METHYL 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N PHENYL 2 [(2 OXO 3 PHENYL 2H [1,2,4] TRIAZINO [2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINOLYSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; INFRARED RADIATION; KIDNEY CANCER; LIQUID CHROMATOGRAPHY; MELANOMA; MOLECULAR DOCKING; PHOTOBACTERIUM LEIOGNATHI; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

EID: 84879693102     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0257-x     Document Type: Article

References (45)

1. 1-adrenoreceptor antagonists. Eur J Med Chem 46:647-658
2. Alafeefy AM, Kadi AA, Al-Deeb OA, El-Tahir KEH, Al-jaber NA (2010) Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives. Eur J Med Chem 45:4947-4952
3. Al-Obaid AM, Abdel-Hamide SG, El-Kashef HA, Abdel-Aziz AA, El-Azab M, AS Al-KhameesHA, El-Subbagh HI (2009) Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs. Eur J Med Chem 44:2379-2391
4. Al-Omary FAM, Hassan GS, El-Messery SM, El-Subbagh HI (2012) Substituted thiazoles V. Synthesis and antitumor activity of novel thiazolo[2, 3-b]quinazoline and pyrido[4, 3-d]thiazolo[3, 2-a]pyrimidine analogues. Eur J Med Chem 47:65-72
5. Aniszewski T (2007) Alkaloids - secrets of life. 316
6. Antipenko LN, Karpenko AV, Kovalenko SI, Katsev AM, Komarovska- Porokhnyavets E, Novikov V, Chekotilo A (2009) Synthesis of new 2-Thio-[1, 2, 4]triazolo[1, 5-c]quinazoline derivatives and its antimicrobial activity. Chem Pharm Bull 57:580-585
7. Armarego WLF (2008) Fused Pyrimidines, Part I, quinazolines. Chem Het Comp 24:518
8. Avendano C, Menendez JC (2008) Medicinal chemistry of anticancer drugs, 1st edn. Elsevier Science. ISBN-10: 0444528245, ISBN-13: 978-0444528247
9. Baxter CA, Murray CW, Waszkowycz B, Li J, Sykes RA, Bone RG, Perkins TD (2000) New approach to molecular docking and its application to virtual screening of chemical databases. J Chem Inf Comput Sci 40:254-262
10. Berest GG, Voskoboynik AY, Kovalenko SI, Sinyak RS, Omelchenko IV, Shishkin OV, Komarovska-Porokhnyavets EZ, Novikov VP (2010) Synthesis of 3-R-6-thio-6, 7-dihydro-2H-[1, 2, 4]triazino[2, 3-c]quinazoline-2-ones and its derivatives, antimicrobial and antifungal activity. J Org Pharm Chem 8:42-52
11. Berest GG, AYu Voskoboynik, Kovalenko SI, Antypenko AM, Nosulenko IS, Katsev AM, Shandrovskaya AS (2011) Synthesis and biological activity of novel N-cycloalkyl-(cycloalkylaryl)-2-[(3-R-2-oxo-2H-[1, 2, 4]triazino[2, 3-c]quinazoline-6-yl)thio]acetamides. Eur J Med Chem 46:6066-6074
12. Berest GG, OYu Voskoboynik, Kovalenko SI, Nosulenko IS, Antypenko LM, Antypenko OM, Shvets VM, Katsev AM (2012) Synthesis of new 6-{[ω- (dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-[1, 2, 4]triazino[2, 3-c]quinazoline-2-ones and evaluation of their anticancer and antimicrobial activities. Sci Pharm 80:37-65
13. Bertelli L, Biagi G, Giorgi I, Livi O, Manera C, Scartoni V, Lucacchini A, Giannaccini G, Barili PL (2000) Substituted 1, 2, 3-triazolo[1, 5-a] quinazolines: synthesis and binding to benzodiazepine and adenosine receptors. Eur J Med Chem 35:333-341
14. Boyd MR (1997) The NCI in vitro anticancer drug discovery screen; concept, implementation and operation. Can Drug Discov Dev 2:23-43
15. Boyd MR, Paull KD (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91-109
16. Cao SL, Guo YW, Wang XB, Zhang M, Feng YP, Jiang YY, Wang Y, Gao Q, Ren J (2009) Synthesis and cytotoxicity screening of piperazine-1-carbodithioate derivatives of 2-Substituted Quinazolin-4(3H)-ones. Arch Pharm 342:182-189
17. Chandrika PM, Yakaiah T, Ram Rao AR, Narsaiah B, Chakra Reddy N, Sridhar V, Venkateshwara Rao J (2008) Synthesis of novel 4, 6-disubstituted quinazoline derivatives, their anti-inflammatory and anti-cancer activity (cytotoxic) against U937 leukemia cell lines. Eur J Med Chem 43:846-852
18. Cummings MD, Des Jarlais RL, Gibbs AC, Mohan V, Jaeger EP (2005) Comparison of automated docking programs as virtual screening tolls. J Med Chem 4:962-976
19. Degtever A, Lugovskoy A, Cardone M (2001) Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xl. Nat Cell Biol 2:173-182
20. Denny WA (2001a) Prodrug strategies in cancer therapy. Eur J Med Chem 36:577-595
21. Denny WA (2001b) The 4-anilinoquinazoline class of inhibitors of the erbB famyli of receptors tyrosine kinases. Farmaco 56:51-56
22. Kidwai M, Venkataramanan R, Mohan R, Sapra P (2002) Chemotherapy and heterocyclic compounds. Curr Med Chem 9:1209-1228
23. Lee J, Kim SJ, Choi H, Kim YH, Lim IT, Yang H, Lee CS, Kang HR, Ahn SK, Moon SK, Kim DH, Lee S, Choi NS, Lee KJ (2010) Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. Med Chem 53:6337-6354
24. Li S, Guo C, Sun X, Li Y, Zhao H, Zhan D, Lan M, Tang Y (2012) Synthesis and biological evaluation of quinazoline and quinoline bearing 2, 2, 6, 6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and EPR bio-probe agents Eur. J Med Chem 49:271-278
25. Lüth A, Löwe W (2008) 4-(Indole-3-yl) quinazolines - a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem 43:1478-1488
26. Michael JP (2005) Quinoline, quinazoline and acridone alkaloids. Nat Prod Rep 22:627-646
27. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766
28. Nosova EV, Lipunova GN, Charuschyn VN (2009) Fluorine-containing quinazolines and their oxa and thia analogues: synthesis and biological activities. Russ Chem Rev 78:387
29. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MRJ (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development mean graph and COMPARE algorithm. J Natl Cancer Inst. 81:1088
30. Pawar VG, Sos ML, Rode HB, Rabiller M, Heynck S, Otterlo WAL, Thomas RK, Rauh D (2010) Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. J Med Chem 53:2892-2901
31. Prendergast GC (ed) (2003) Molecular cancer therapeutics: strategies for drug discovery and development 363. http://www.eyesopen.com/documentation
32. Rather BA, Raj T, Reddy A, Ishar MPS, Sivakumar S, Paneerselvam P (2010) Synthesis and evaluation of novel 2-substituted-quinazolin-4(3H)-ones as potent analgesic and anti-inflammatory agents. Arch Pharm 343:108-113
33. Redondo M, Zarruk JG, Ceballos P, Pérez DI, Pérez C, Perez-Castillo A, Moro MA, Brea J, Val C, Cadavid MI, Loza MI, Campillo NE, Martínez A, Gil C (2012) Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. Eur J Med Chem 47:175-185
34. Rewcastle GW, Denny WA, Showalter DHH (2000) Synthesis of 4-(phenylamino)pyrimidine derivatives as ATP-competitive protein kinase inhibitors with potential for cancer chemotherapy. Curr Org Chem 4:679-706
35. Richter S, Gioffreda B (2011) Synthesis, molecular modelling and biological evaluation of 4-amino-2(1H)-quinazolinone and 2,4-(1H, 3H)-quinazolidone derivatives as antitumor agents. Archive der Pharmazie 344:810-820
36. Rohini R, Shanker K, Reddy PM, Ho YP, Ravinder V (2009) Mono and bis-6-arylbenzimidazo[1, 2-c]quinazolines: a new class of antimicrobial agents. Eur J Med Chem 44:3330-3339
37. Schulz-Gasch T, Stahl M (2003) Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J Mol Model 9:47-57
38. Schulz-Gasch T, Stahl M (2004) Scoring functions for protein-ligand interactions: a critical perspective. Drug Disc Today 3:231239
39. Sharma VM, Seshu KVA, Sekhar VC, Madan S, Vishnu B, Babu PA, Krishna CV, Sreenu J, Krishna VR, Venkateswarlu A, Rajagopal S, Ajaykumar R, Kumar TS (2004) Synthesis and biological evaluation of [4-(2-phenylethenesulfonylmethyl)phenyl] quinazolin-4-yl-amines as orally active anti-cancer agents. Bioorg Med Chem Lett. 14:67-71
40. Shoemaker RH, Scudiero DA, Melillo G (2002) Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem 2:229-246
41. Technical documentation for OpenEye Software. Omega, Fred, OpenEye Scientific Software. (2005)
42. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343-349
43. Yadav MR, Grande F, Chouhan BS, Naik PP, Giridhar R, Garofalo A, Neamati N (2012) Cytotoxic potential of novel 6, 7-dimethoxyquinazolines. Eur J Med Chem 48:231-243
44. Zaharevitz DW, Holbeck SL, Bowerman C, Svetli PA (2002) COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition. J Mol Graphics Modell 20:297-303
45. Zhang Y, Chen Z, Lou Y, Yu Y (2009) 2, 3-Disubstituted 8-arylamino-3H-imidazo[4, 5-g] quinazolines: a novel class of antitumor agents. Eur J Med Chem 44:448-452